Status:
TERMINATED
Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
Lead Sponsor:
Ohio State University Comprehensive Cancer Center
Collaborating Sponsors:
Roche Pharma AG
Conditions:
Tumors
Unknown Primary Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This study will determine the maximum tolerated dose of the triplet combination of capecitabine that can be administered in combination with weekly paclitaxel and every four weeks with carboplatin.
Detailed Description
Rationale: The combination of the chemotherapy drugs paclitaxel and carboplatin is one of the most common combination regimens used in clinical practice for cancer. These agents are used for a variety...
Eligibility Criteria
Inclusion
- Inclusion Criteria for Phase I:
- All advanced solid malignancies
- Any prior chemotherapy permitted
- Performance Status 0-2
- Inclusion Criteria for Phase II:
- Adenocarcinoma of unknown primary
- No prior chemo permitted
- Performance Status 0-2
Exclusion
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2013
Estimated Enrollment :
57 Patients enrolled
Trial Details
Trial ID
NCT00201734
Start Date
June 1 2005
End Date
June 1 2013
Last Update
September 23 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States, 43210